Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
申请人:Cymabay Therapeutics, Inc.
公开号:US10292983B2
公开(公告)日:2019-05-21
Use of oxymethylene aryl GPR119 agonists, and optionally DPP IV inhibitors and optionally metformin, for the treatment of inflammatory gastrointestinal diseases or gastrointestinal conditions involving malabsorption of nutrients and/or fluids are provided.
提供了氧亚甲基芳基 GPR119 激动剂、可选的 DPP IV 抑制剂和可选的二甲双胍用于治疗炎症性胃肠道疾病或涉及营养和/或液体吸收不良的胃肠道疾病。